Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: April 2007
-
By Jason Derry — On Wednesday, Roche announced that it would acquire BioVeris Corporation for about $600 million. The purchase of BioVeris will allow Roche to expand its immunochemistry business into the life science research and development, drug discovery, and clinical research areas. Roche’s announcement that it would be acquiring BioVeris came two…
-
By Donald Zuhn — On March 21, 2007, Aegerion Pharmaceuticals Inc. filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock. According to a Reuters report, while neither the number of shares in the offering nor the offering price have been determined,…
-
By Kevin E. Noonan The Wisconsin Alumni Research Foundation (WARF) owns the most significant U.S. patents protecting human embryonic stem cell technology. These patents, U.S. Patent Nos. 5,843,780 (claiming primate embryonic stem (pES) cells); 6,200,806 (claiming human embryonic stem cell (hES) cells); and 7,029,913 (hES) (collectively, the Thomson patents) were challenged in a…
-
By Christopher P. Singer Transition Therapeutics, Inc. announced in an April 3, 2007 press release that its investigational Alzheimer’s disease drug, AZD-103/ELND005, developed in collaboration with Elan Corporation, plc has received Fast Track designation from the FDA. The drug is currently undergoing Phase I clinical trials, and is expected to enter Phase II…
-
By Kevin E. Noonan — The institutional history of the Court of Appeals for the Federal Circuit (CAFC) in recent years has been one of constant reversal by the U.S. Supreme Court. In procedural matters (eBay Inc. v. MercExchange, LLC), the Federal Circuit’s prerogatives on the standard of review (Dickinson v. Zurko), and…
-
By Mark Chael — On March 30, 2007, Cephalon, Inc. announced that it had received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding Cephalon’s Nuvigil® (armodafinil) new drug application (NDA). The approvable letter was accompanied by draft labeling that includes a proposed warning section in bold type describing a…
-
By Christopher P. Singer — As previously reported on Patent Docs, the PCT has amended portions of its Regulations, effective on April 1, 2007. Most notably, the amendments provide: (a) a way for an applicant to request that the right to claim priority be restored in applications that meet specific requirements; (b) a…
-
The Federal Circuit Continues Its Capitulation on Declaratory Judgment Actions By Kevin E. Noonan — In its MedImmune, Inc. v. Genentech, Inc. decision, the Supreme Court suggested in dicta that the Federal Circuit’s "reasonable apprehension of (imminent) suit" test was in conflict with Supreme Court precedent, but limited this dicta to a footnote. …
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Abbott Laboratories et. al. v. Sandoz, Inc. et. al.1:07-cv-01721; filed March 28, 2007 in the Northern District of Illinois Infringement of U.S.…
-
April 13, 2007 – "Of Brics & Mortar: Technological Drivers in Booming Economies" Symposium (Northwestern Journal of Technology and Intellectual Property) – Chicago, IL April 16-18, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources Group) – Orlando, FL April 19-20, 2007 – "Litigation and Enforcement in the Biotech and Pharmaceutical Industry" (GTCbio)…
Patent Docs 